Latest news with #Australian-founded
Malaysian Reserve
3 days ago
- Business
- Malaysian Reserve
Payments Platform Optty Kicks Off Next Stage of Growth with Appointment of Industry Leader Richard Miller as New CEO
SYDNEY, June 30, 2025 /PRNewswire/ — Optty™, the Australian-founded global payments technology company, has appointed global industry leader Richard Miller as its new Chief Executive Officer, effective immediately. Alan Miltz, Chairman of Optty said: 'As CEO, Richard Miller will lead Optty's next phase of global expansion, scaling and streamlining our pioneering platform that connects more than 145 payment methods (including digital wallets, Buy Now Pay Later (BNPLs) and credit/debit cards) through a single integration.' Optty's Board of Directors sees Miller's appointment as key to Optty's commitment to growth through partnerships, financial inclusion and product innovation. Miller will continue to build enduring relationships with merchants, processors and payment providers as the Singapore-headquartered company scales up. Miller says: 'I'm thrilled to join Optty at this pivotal time. Optty has built an extraordinary proposition that simplifies and accelerates eCommerce and in-person payments for the world's merchants, processors and acquirers. In a world where ways to pay have proliferated, Optty offers a uniquely powerful solution to simplify the technical challenge of offering broad consumer choice.' 'It will be my privilege to lead Optty's dedicated team as we work with our partners around the world to unlock the next wave of value and impact.' Miller's experience spans more than two decades of global leadership in fintechs, payments, and strategic consulting. His previous senior roles include ConnectID/ Australian Payments Plus, Deloitte, National Australia Bank and The Boston Consulting Group. Miller is widely respected across the Australian and international payments landscape for his strategic insight, collaborative leadership and deep industry expertise. Miltz said: 'Richard brings a rare combination of strategic clarity and execution experience across global payments. His leadership, deep fintech expertise, and commitment to partnership will be critical to delivering on our global ambitions. The Board and I are delighted to welcome Richard's appointment as CEO.' 'For Optty it marks a significant step as we scale our reach and relevance in what is a rapidly evolving global payments landscape.' 'We would also like to thank Steven Ritchie for his exceptional leadership as interim CEO and are pleased to announce that Steven will continue to help lead the business in an expanded capacity as Chief Operating Officer.' For interviews/more contact Media@ About Optty: Optty is a global payments infrastructure platform for PSPs, gateways, acquirers and merchants that provides a single integration to 145+ payment partners in 140 countries and 120 currencies (and growing). Optty empowers partners to access and provide payment innovation at scale, enabling them to add local payment methods across nine payment types; BNPL, digital wallets, credit/debit, gift cards/virtual cards, crypto, pay with points, open banking, P2P and payouts as well as additional value-added services in ESG, Fraud Prevention and Tokenization. Optty's simplified API integration requires no further development for any payment methods to be enabled, saving thousands of development hours for partners and merchants alike. Optty is a Certified B Corp, founded out of Australia and the UK, headquartered in Singapore and global in its service coverage. Optty powers limitless ways to pay with unrivalled simplicity. Media@
Yahoo
12-06-2025
- Entertainment
- Yahoo
Christian rock band respond to former member's drug abuse, sexual assault allegations
Nashville-based Christian rockers Newsboys are responding to troubling news regarding their 59-year-old former lead singer, Michael Tait. In a post on the group's official Instagram account, the Australian-founded band responded to allegations of drug abuse and inappropriate sexual conduct against Tait while also distancing him from the band. "Last night, our hearts were shattered when we read the news alleging drug abuse and inappropriate sexual actions by our former lead singer, Michael Tait. While Michael has not addressed these allegations, we are devastated even by the implications," the statement read. "First and foremost, our hearts are with the victims who have bravely shared their stories. If you are a victim, we urge you to come forward. We absolutely do not condone any form of sexual assault." The quartet noted that as husbands who are fathers of 14 children in total, they were "horrified, heartbroken, and angry at this report and in many ways, we feel as if we and our families have been deceived for the last fifteen years." In January 2025, Tait, who was the lead vocalist of the group for 15 years in their four decades of existence, offered the following in a statement: "Fifteen years ago, my life was forever changed when I received the invite to step into the role of lead singer for Newsboys. The years since have been some of the most fulfilling, faith-filled, and rewarding years of my life." "I have been on an amazing journey all over the globe, performing and ministering to people of all ages, races, and backgrounds." "The decision does not come lightly and has been a shock to even myself, but admist prayer and fasting, I have clarity that this is the right decision," the statement continued. In their June 5 statement, Tait's former bandmates, Duncan Phillips, Jeff Frankenstein, Jody Davis and Adam Agee, noted that when he left the band, he "confessed" to them and their management that he "had been living a double-life." Through a nearly three-year-long investigation by The Roys Report, it was discovered that for two decades, Tait befriended three young men on Christian music tours in 2004, 2010, and 2014. The trio were all 22 at the time of their first interaction. Allegations of Tait, then two decades older than his accusers, engaging in acts of sexual assault and grooming highlight the lengthy of June 5, Tait has not officially responded to the allegations on his social media accounts or the statement from his former bandmates. As well, there have been no further comments from the group. Upon their 2021 release of "Stand," their 20th studio album, the band spoke with The Nashville Tennessean, part of the USA TODAY Network. It's noted that when Grammy-winner Tait, formerly of DC Talk, replaced Peter Furler as the group's new lead vocalist in 2009, the band no longer had any original members in its ranks. This article originally appeared on Nashville Tennessean: Newsboys address sex assault allegations against member Michael Tait
USA Today
06-06-2025
- Entertainment
- USA Today
Christian rock band respond to former member's drug abuse, sexual assault allegations
Christian rock band respond to former member's drug abuse, sexual assault allegations Nashville-based Christian rockers Newsboys are responding to troubling news regarding their 59-year-old former lead singer, Michael Tait. In a post on the group's official Instagram account, the Australian-founded band responded to allegations of drug abuse and inappropriate sexual conduct against Tait while also distancing him from the band. "Last night, our hearts were shattered when we read the news alleging drug abuse and inappropriate sexual actions by our former lead singer, Michael Tait. While Michael has not addressed these allegations, we are devastated even by the implications," the statement read. "First and foremost, our hearts are with the victims who have bravely shared their stories. If you are a victim, we urge you to come forward. We absolutely do not condone any form of sexual assault." The quartet noted that as husbands who are fathers of 14 children in total, they were "horrified, heartbroken, and angry at this report and in many ways, we feel as if we and our families have been deceived for the last fifteen years." Tait told the band he had 'been living a double-life' In January 2025, Tait, who was the lead vocalist of the group for 15 years in their four decades of existence, offered the following in a statement: "Fifteen years ago, my life was forever changed when I received the invite to step into the role of lead singer for Newsboys. The years since have been some of the most fulfilling, faith-filled, and rewarding years of my life." "I have been on an amazing journey all over the globe, performing and ministering to people of all ages, races, and backgrounds." "The decision does not come lightly and has been a shock to even myself, but admist prayer and fasting, I have clarity that this is the right decision," the statement continued. In their June 5 statement, Tait's former bandmates, Duncan Phillips, Jeff Frankenstein, Jody Davis and Adam Agee, noted that when he left the band, he "confessed" to them and their management that he "had been living a double-life." Through a nearly three-year-long investigation by The Roys Report, it was discovered that for two decades, Tait befriended three young men on Christian music tours in 2004, 2010, and 2014. The trio were all 22 at the time of their first interaction. Allegations of Tait, then two decades older than his accusers, engaging in acts of sexual assault and grooming highlight the lengthy investigation. Latest on Michael Tait As of June 5, Tait has not officially responded to the allegations on his social media accounts or the statement from his former bandmates. As well, there have been no further comments from the group. Upon their 2021 release of "Stand," their 20th studio album, the band spoke with The Nashville Tennessean, part of the USA TODAY Network. It's noted that when Grammy-winner Tait, formerly of DC Talk, replaced Peter Furler as the group's new lead vocalist in 2009, the band no longer had any original members in its ranks.
Business Upturn
28-05-2025
- Business
- Business Upturn
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
Sydney, Australia: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. This press release features multimedia. View the full release here: Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. 'Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials,' said Minister Chanthivong. 'I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues.' Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. 'We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea,' said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. 'This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market.' The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results For more information or to speak to an expert team member visit View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Yahoo
27-05-2025
- Business
- Yahoo
New South Wales Minister for Industry and Trade Visits Novotech Seoul Office to Strengthen Clinical Trial Collaboration
SYDNEY, May 27, 2025--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase, was honored to welcome The Hon. Anoulack Chanthivong, New South Wales (NSW) Minister for Industry and Trade, to its Seoul office on May 19. The Minister's visit highlights a deepening collaboration between South Korea and Australia in the field of clinical research and highlights the strategic importance of cross-border partnerships in advancing global drug development. "Novotech is a fantastic success story demonstrating the global value of NSW's strengths in life sciences and clinical trials," said Minister Chanthivong. "I was thrilled to learn about Novotech's growth in the Republic of Korea and the central role their business plays in bringing Korean biotech innovation to the world. Investment NSW looks forward to continuing to support Novotech as it generates export dollars for our state while helping people around the world tackle serious health issues." Minister Chanthivong was joined by a delegation including: Brooke O'Rourke, Chief of Staff to Minister Chanthivong. Rebecca McPhee, Deputy Secretary of Investment NSW. David Lawson, NSW Trade & Investment Commissioner for Japan & Korea. Yoojin Kim, NSW Trade & Investment Director for Korea. The delegation engaged with Novotech leaders Dr. Yooni Kim, Hyun Kim, and Lilian Kim, who shared insights into Novotech's growth as a global clinical research organization and the expanding role of South Korea as a premier destination for clinical trials. "We are honored that the Australian NSW Trade Minister and senior officials from NSW Investment have selected Novotech as a leading example of collaboration between Australia and South Korea," said Dr. Yooni Kim, Managing Director – Asia-Pacific at Novotech. "This visit reinforces the strong and growing partnership between the two countries in the clinical research and biopharmaceutical sector. As the largest Australian-founded global services company operating in South Korea, Novotech is committed to creating more success stories that demonstrate the value of this collaboration. I believe Novotech's strong partnership with the Australian NSW government and their NSW Investment can mutually benefit Korean biotech companies and the Australian clinical trial market." The discussion reinforced Novotech's strong partnership with Australia, supported by a track record of successful clinical trials and a shared vision for future innovation. With increasing interest from Korean biotechs to conduct research in Australia, both parties explored opportunities to enhance bilateral cooperation and accelerate cross-border clinical development. Novotech, recently recognized as the Best CRO in Australia by IMAPAC's Asia-Pacific Biopharma Excellence Awards, continues to solidify its position as the region's leading clinical development partner. The company offers Korean biotech sponsors seamless access to Australia's world-class research infrastructure, regulatory expertise, and accelerated clinical pathways. Through its integrated full-service model, Novotech enables Korean biotechs to confidently expand early-phase programs into Australia, backed by deep regional knowledge and globally aligned operational standards. About Novotech Novotech is a globally recognized full-service clinical research organization (CRO) and scientific advisory company trusted by biotech and small- to mid-sized pharmaceutical companies to guide drug development at every phase. With a global footprint that includes 30+ offices across the Asia-Pacific region, North America, and Europe and partnerships with 5,000+ trial sites, Novotech provides clients an accelerated path to bring life-changing therapies to market by providing access to key clinical trial destinations and diverse patient populations. Through its client-centric service model, Novotech seamlessly integrates people, processes, and technologies to deliver customized solutions that accelerate the path to market for life-changing therapies. By adopting a true partnership approach, Novotech shares a steadfast commitment to client success, empowering innovation, and advancing healthcare worldwide. Recipient of numerous industry accolades, including the Frost & Sullivan CRO Company of the Year award for 19 consecutive years, Novotech is recognized for its excellence in clinical trial execution and innovation. Its deep therapeutic and regulatory expertise, combined with local market insights, ensures streamlined clinical trials, optimized data analytics, and accelerated patient recruitment strategies. Together with clients, Novotech transforms scientific advancements into therapies that improve global health outcomes, embodying a mission of driving innovation and delivering impactful results For more information or to speak to an expert team member visit View source version on Contacts Media Contact Toyna Chin mediacontact@ USA: +1 415 364 8135 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
